COMP <GO>
CRL vs IQV // EV/EBITDA & P/E VALUATION
Charles River Laboratories International Inc. (NYSE) VS. IQVIA Holdings Inc. (NYSE) • 15-METRIC TALLY: CRL 3
— IQV 8
▲ EV/EBITDA & P/E VALUATION LEADER: IQV
LAST: $359.41 (-4.44%) • MKT CAP: $17.95B
valuation
95.0x
LAST: $267.33 (-2.81%) • MKT CAP: $45.33B
valuation
20.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRL VS. IQV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRL | IQV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.40% | 9.40% | -9.00 | IQV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 95.0x | 20.4x | +74.60 | IQV | /valuation <GO> |
| Free Cash Flow Yield | 3.10% | 4.24% | -1.14 | IQV | /fcf-yield <GO> |
| Operating Margin | 0.60% | 13.40% | -12.80 | IQV | /operating-margins <GO> |
| Net Profit Margin | -3.60% | 8.30% | -11.90 | IQV | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 5.90% | -6.80 | IQV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.65 | 2.22 | +1.43 | CRL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 6/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.7 | 55.7 | +17.00 | CRL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.16 | -0.01 | IQV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 31.0x | -8.00 | CRL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.95B | $45.33B | -$27.38B | IQV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRL REV | IQV REV | CRL GROSS % | IQV GROSS % | CRL FCF | IQV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.02B | $16.31B | — | — | $557.0M | $1.92B |
| FY 2024 | $4.05B | $15.40B | — | — | $552.3M | $2.02B |
| FY 2023 | $4.13B | $14.98B | — | — | $498.1M | $1.47B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRL // BETA 1.15
IQV // BETA 1.16